Amid the coronavirus pandemic, the US Food and Drug Administration has issued guidance on potency assays for manufacturers of monoclonal antibodies and other therapeutic proteins to treat COVID-19.
The coronavirus disease 2019 (COVID-19) pandemic was a catalyzing event in the rapid progression of the messenger RNA (mRNA) vaccine technology to successful product delivery 1,2. The promise of this ...
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the coronavirus disease 2019 (COVID-19) pandemic. Soon after COVID-19 was declared a global pandemic, an ...
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the coronavirus disease 2019 (COVID-19) pandemic. Since the beginning of the pandemic, several SARS ...
An integrated suite of bioassays provides a coherent workflow to track antibody Fc effector activity across every stage of mAb drug development Potency assays that fail during tech transfer or ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results